Close

Press Releases

Chugai Pharmaceutical Co Ltd. to Take Part in โ€œRelay for Life Japanโ€ Using โ€œ3D Adventure Experience (Lung Cancer)โ€ to promote awareness of the early...

Chugai Pharmaceutical Co Ltd announced that its co-sponsorship of โ€œRelay for Life Japanโ€ (Organizer: Japan Cancer Society etc.), a charity activity aiming to support cancer patients and their families, and encourage the entire community to confront and conquer cancer...

Pfizer reports Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBAยฎ (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies,...

Pfizer Announces Results From Two Phase 3 TRUMENBA Studies At The European Society For Paediatric Infectious Diseases Meeting

Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBAยฎ (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. ย  ]The two...

EU approves Alprolix (rFIXFc) for the Treatment of Haemophilia B

First Fc Fusion Therapy Approved for haemophilia B in the EU to Provide Extended Protection Against Bleeds Swedish Orphan Biovitrum AB and Biogen announced that the European Commission (EC) has approved Alprolixยฎ (rFIXFc), their extended half-life...

Immunosup pressant CellCept Obtained Approval for Additional Indication of โ€œLupus Nephritisโ€

Chugai Pharmaceutical Co Ltd. announced that it obtained a supplemental approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 13, 2016, for โ€œCellCeptยฎ. Capsules 250โ€ and โ€œCellCeptยฎ Powder for Oral Suspension 31.8%โ€...

AbbVie Inc to participate at the UBS Global Health Care Conference

AbbVie will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 1:00 p.m. Central time. ...

Mylan Launches Generic Frova Tablets for for migraine headaches in adults.

Mylan N.V. announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frovaยฎ Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป